||

Update 14 18th January

Update 14, 18th January 2010

 

Current availability from NIBSC of candidate influenza vaccine viruses,SRD reagents and neuraminidase reagents for use in the 2010 southern hemisphere season and  2009/2010 northern hemisphere season (see below for pricing information)

 

Update 14, 18th January 2010

 

Southern Hemisphere 2010 1

 

Candidate influenza vaccine viruses

NIBSC code

H1N1 2

 

A/California/7/2009 wild type virus 3

09/104

NYMC X-179A reassortant derived from A/California/7/2009

09/216

NYMC X-181 reassortant derived from A/California/7/2009

09/176

NYMC X-181A reassortant derived from A/California/7/2009

09/178

IVR-153 reassortant derived from A/California/7/2009

09/236

NIBRG-121 reassortant derived from A/California/7/2009

09/122

NIBRG-121xp reassortant derived from A/California/7/2009

09/268

NIBRG-122 reassortant derived from A/England/195/2009

09/130

H3N2

 

A/Perth/16/2009 wild type virus

09/208

NIB-64 reassortant derived from A/Perth/16/2009

09/206

NYMC X-183 reassortant derived from A/Wisconsin/15/2009 09/248
 NYMC X-185 reassortant derived from A/Wisconsin/15/2009

09/274

Available w/c 01Feb’10

B

 

B/Brisbane/60/2008

09/168

B/Brisbane/33/2008

08/280 or 08/298

NYMC BX-31 reassortant derived from B/Brisbane/60/2008

08/360

NIB-58 reassortant derived from B/Brisbane/60/2008

08/364

 

1 Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season

2 For further information on the candidate (H1N1)v vaccine viruses

3 Wild type (H1N1)v virus should be handled according to WHO recommendations

 

 

Reagents for influenza vaccine standardisation

NIBSC code

H1N1

 

A/California/7/2009 (NYMC X-179A) egg derived antigen

09/146

A/California/7/2009 (NYMC X-179A) cell derived antigen

09/174

A/California/7/2009 (NIBRG-121xp) egg derived antigen

09/196

A/California/7/2009 antiserum

09/152

H3N2

 

A/Perth/16/2009 like antigen

tbc

A/Perth/16/2009 like antiserum

09/270

B

 

B/Brisbane/60/2008 like antigen

08/352

B/Brisbane/60/2008 like antiserum

08/354

 

Neuraminidase reagents

NIBSC code

N1

 

antiserum prepared from A/New Caledonia/20/99

04/230

N2

 

antiserum prepared from A/Wyoming/3/2003

04/258

B

 

NA antiserum prepared from B/Jiangsu/10/2003

04/228

NA antiserum prepared from B/Malaysia/2506/2004

05/252

NA antiserum prepared for B/Florida/4/2006 under development

To be confirmed

 

Northern Hemisphere 2009/2010 4

 

Candidate influenza vaccine viruses

NIBSC code

H1N1

 

A/Brisbane/59/2007

tbc

IVR-148 reassortant derived from A/Brisbane/59/2007

08/300

H3N2

 

A/Brisbane/10/2007 wild type virus

07/250

A/Uruguay/716/2007 wild type virus-

07/354

NIB-50 reassortant derived from A/Uruguay/716/2007

07/358

IVR-149 reassortant derived from A/Uruguay/716/2007

07/362

NYMC X-175C reassortant derived from A/Uruguay/716/2007

08/304

B

 

B/Brisbane/60/2008

09/168

B/Brisbane/33/2008

08/280

NYMC BX-31 reassortant derived from B/Brisbane/60/2008

08/360

NIB-58 reassortant derived from B/Brisbane/60/2008

08/364

4WHO recommended composition of influenza virus vaccines for use in the 2009/2010 northern hemisphere influenza season

 

Reagents for influenza vaccine standardisation

NIBSC code

H1N1

 

A/Brisbane/59/2007 IVR-148 antigen

08/100

A/Brisbane/59/2007 IVR-148 antiserum

08/112

H3N2

 

A/Brisbane/10/2007-like antigen (NYMC X-175C derived from A/Uruguay/716/2007)

08/278

A/Brisbane/10/2007-like antiserum (NYMC X-175C derived from A/Uruguay/716/2007)

08/246

B

 

B/Brisbane/60/2008 like antigen

08/352

B/Brisbane/60/2008 like antiserum

08/354

 

Neuraminidase reagents

NIBSC code

N1

 

antiserum prepared from A/New Caledonia/20/99

04/230

N2

 

antiserum prepared from A/Wyoming/3/2003

04/258

B

 

NA antiserum prepared from B/Jiangsu/10/2003

04/228

NA antiserum prepared from B/Malaysia/2506/2004

05/252

NA antiserum prepared for B/Florida/4/2006 under development

To be confirmed

 

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the usual NIBSC handling charge of £63 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the £63 handling fee.